Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif., June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured,...Read more
90th participant enrolled in landmark clinical trial in patients with Major Depressive Disorder Targets October 2025 for initial results presentation Vancouver, British Columbia – TheNewswire - June 18, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt:...Read more
Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the genomic instability of...Read more
Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) Patients with relapsed or refractory FL achieved significantly improved progression-free survival...Read more
Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9% of Participants Remained HIV Negative on Twice-Yearly Injectable Yeztugo Yeztugo, Nearly 20 Years in the Making, Represents a Major Breakthrough in the Fight Against HIV FOSTER CITY, Calif. / Jun 18, 2025 / Business Wire...Read more
FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approval Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk...Read more
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Vertex Pharmaceuticals | 6.41 1.45 | $448.40 |
| GRAIL | 6.39 15.20 | $48.44 |
| Scholar Rock | 5.17 16.60 | $36.32 |
| Bolt Biotherapeutics | 5.10 912.52 | $5.66 |
| United Therapeutics | 4.84 1.69 | $291.72 |
| Medpace | 4.77 1.60 | $302.69 |
| Regeneron Pharmaceuticals | 4.72 0.93 | $513.58 |
| McKesson | 4.53 0.63 | $728.91 |
| Quantum BioPharma | 4.47 17.37 | $30.20 |
| HCA Healthcare | 4.41 1.18 | $376.86 |
| National HealthCare | 4.20 4.12 | $106.04 |
| Alnylam Pharmaceuticals | 3.61 1.17 | $312.32 |
| Nutex Health | 3.50 3.03 | $119.00 |
| Masimo | 3.45 2.17 | $162.77 |
| Natera | 3.43 2.05 | $170.98 |
| Semler Scientific | 3.41 11.95 | $31.94 |
| Madrigal Pharmaceuticals | 3.12 1.12 | $282.72 |
| Molina Healthcare | 2.94 1.01 | $295.34 |
| Company | Volume | Last Trade |
|---|---|---|
| Healthcare Triangle | 431,572,371 | $0.03 |
| Aptevo Therapeutics | 123,560,236 | $5.00 |
| Helius Medical Technologies | 66,828,404 | $0.37 |
| NuCana | 60,711,935 | $0.12 |
| Biodexa Pharmaceuticals | 54,444,180 | $1.03 |
| Oscar Health | 48,126,255 | $18.82 |
| Pfizer | 35,432,789 | $23.88 |
| Recursion | 34,891,557 | $5.11 |
| Incannex Healthcare | 30,820,978 | $0.22 |
| Azitra | 27,859,804 | $0.26 |
| GeoVax Labs | 25,570,430 | $0.93 |
| Plus Therapeutics | 23,046,548 | $0.21 |
| Biomea Fusion | 21,079,287 | $1.91 |
| Merck | 19,610,577 | $79.29 |
| PacBio | 19,507,367 | $1.31 |
| Proces Pharmaceuticals | 18,494,752 | $0.25 |
| bioAffinity Technologies | 18,074,390 | $0.25 |
| Bristol-Myers Squibb | 15,303,078 | $46.80 |
| Immuneering | 13,167,131 | $2.77 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
